Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background A major challenge for randomized phase III oncology trials is the frequent low rates of patient enrollment, resulting in high rates of premature closure due to insufficient accrual. Purpose We conducted a pilot study to determine the extent of trial closure due to poor accrual, feasibility of identifying trial factors associated with sufficient accrual, impact of redesign strategies on trial accrual, and accrual benchmarks designating high failure risk in the clinical trials cooperative group (CTCG) setting. Methods A subset of phase III trials opened by five CTCGs between August 1991 and March 2004 was evaluated. Design elements, experimental agents, redesign strategies, and pretrial accrual assessment supporting accrual predictions were abstracted from CTCG documents. Percent actual/predicted accrual rate averaged per month was calculated. Trials were categorized as having sufficient or insufficient accrual based on reason for trial termination. Analyses included univariate and bivariate summaries to identify potential trial factors associated with accrual sufficiency. Results Among 40 trials from one CTCG, 21 (52.5%) trials closed due to insufficient accrual. In 82 trials from five CTCGs, therapeutic trials accrued sufficiently more often than nontherapeutic trials (59% vs 27%, p = 0.05). Trials including pretrial accrual assessment more often achieved sufficient accrual than those without (67% vs 47%, p = 0.08). Fewer exclusion criteria, shorter consent forms, other CTCG participation, and trial design simplicity were not associated with achieving sufficient accrual. Trials accruing at a rate much lower than predicted (<35% actual/predicted accrual rate) were consistently closed due to insufficient accrual. Limitations This trial subset under-represents certain experimental modalities. Data sources do not allow accounting for all factors potentially related to accrual success. Conclusion Trial closure due to insufficient accrual is common. Certain trial design factors appear associated with attaining sufficient accrual. Defining accrual benchmarks for early trial termination or redesign is feasible, but better accrual prediction methods are critically needed. Future studies should focus on identifying trial factors that allow more accurate accrual predictions and strategies that can salvage open trials experiencing slow accrual. Clinical Trials 2010; 7: 312—321. http://ctj.sagepub.com
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Equipoise and the Ethics of Clinical Research
Freedman, B. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707163170304 · Cited by 2,339 · cited 1×
“Currently, there are no requirements for a proposed trial to demonstrate that the trial addresses clinically relevant uncertainty among a community of clinicians, though the importance of clinical equipoise is acknowledged [19].”
BackgroundMcDonald, A. M., Knight, R. C., Campbell, M. K., Entwistle, V. A., Grant, A. M., Cook, J. A., Elbourne, D. R., Francis, D., Garcia, J., Roberts, I., et al. (2006) · Trials · doi:10.1186/1745-6215-7-9 · Cited by 946
Barriers to Participation in Randomised Controlled Trials
Ross, S., Grant, A., Counsell, C., Gillespie, W., Russell, I., & Prescott, R. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00141-9 · Cited by 907
Campbell, M., Snowdon, C., Francis, D., Elbourne, D., McDonald, A., Knight, R., Entwistle, V, Garcia, J., Roberts, I., Grant, A., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11480 · Cited by 433
Factors that limit the quality, number and progress of randomised controlled trials
Prescott, Counsell, Gillespie, Grant, Russell, Kiauka, Colthart, Ross, Shepherd, & Russell (1999) · Health Technology Assessment · doi:10.3310/hta3200 · Cited by 390 · cited 1×
“Additional trial data reflected a priori hypotheses about factors impacting accrual success as supported by the literature on accrual barriers [3].”
BackgroundFayter, D., McDaid, C., & Eastwood, A. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.12.013 · Cited by 112 · cited 1×
“Certain reasons previously cited as affecting accrual success, such as clinical relevance of the scientific question and control arm deviation from standard therapy [6,22], could not be identified in this study.”
Background
Cited by
Fogel, D. B. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.001 · Cited by 1,035
Prevalence, Characteristics, and Publication of Discontinued Randomized Trials
Kasenda, B., von Elm, E., You, J., Blümle, A., Tomonaga, Y., Saccilotto, R., Amstutz, A., Bengough, T., Meerpohl, J. J., Stegert, M., et al. (2014) · JAMA · doi:10.1001/jama.2014.1361 · Cited by 415
Bentley, C., Cressman, S., van der Hoek, K., Arts, K., Dancey, J., & Peacock, S. (2019) · Clinical Trials · doi:10.1177/1740774518820060 · Cited by 104
Predicting Low Accrual in the National Cancer Institute’s Cooperative Group Clinical Trials
Bennette, C. S., Ramsey, S. D., McDermott, C. L., Carlson, J. J., Basu, A., & Veenstra, D. L. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv324 · Cited by 108
Habib, D. R. S., Mahajan, I., Evancha, B., Micheel, C., & Fabbri, D. (2025) · Journal of Medical Systems · doi:10.1007/s10916-025-02303-y · Cited by 3
“Clinical trials are necessary for medical innovation, but recruitment remains a substantial obstacle [1, 2].”
Metadata
- Authors
- Schroen, A. T., Petroni, G. R., Wang, H., Gray, R., Wang, X. F., Cronin, W., Sargent, D. J., Benedetti, J., Wickerham, D. L., Djulbegovic, B., & Slingluff, C. L.
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2010-07-01
- Volume
- 7
- Issue
- 4
- Pages
- 312-321
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W2156894466
- Cited by
- 101
- References
- 6
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.